Advantages of nanocarriers for basic research in the field of traumatic brain injury

作     者：Xingshuang Song Yizhi Zhang Ziyan Tang Lina Du Xingshuang Song;Yizhi Zhang;Ziyan Tang;Lina Du

作者机构：School of Pharmaceutical SciencesShandong University of Traditional Chinese MedicineJinanShandong ProvinceChina Department of PharmaceuticsBeijing Institute of Radiation MedicineBeijingChina 

出 版 物：《Neural Regeneration Research》 (中国神经再生研究（英文版）)

年 卷 期：2024年第19卷第2期

页      面：237-245页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 07[理学] 1001[医学-基础医学(可授医学、理学学位)] 070205[理学-凝聚态物理] 10[医学] 0702[理学-物理学] 

基　　金：supported by the Natural Science Foundation of Beijing No.L222126(to LD)。 

主　　题：blood-brain barriers brain targeting central nervous system extracellular vesicles inflammatory factor microglial cell nanocarriers nanoparticles neural restoration traumatic brain injury 

摘      要：A major challenge for the efficient treatment of traumatic brain injury is the need for therapeutic molecules to cross the blood-brain barrier to enter and accumulate in brain tissue.To overcome this problem,researchers have begun to focus on nanocarriers and other brain-targeting drug delivery systems.In this review,we summarize the epidemiology,basic pathophysiology,current clinical treatment,the establishment of models,and the evaluation indicators that are commonly used for traumatic brain injury.We also report the current status of traumatic brain injury when treated with nanocarriers such as liposomes and vesicles.Nanocarriers can overcome a variety of key biological barriers,improve drug bioavailability,increase intracellular penetration and retention time,achieve drug enrichment,control drug release,and achieve brain-targeting drug delivery.However,the application of nanocarriers remains in the basic research stage and has yet to be fully translated to the clinic.